BCR-ABL1 TKIs in Relapsed/Refractory CML

EP. 1: CML as an Ideal Cancer for Targeted Therapy With TKI

June 24th 2019

EP. 2: BCR-ABL1-Targeted TKIs in Treatment of CML

June 24th 2019

EP. 3: Response Monitoring of Patients With CML Treated With TKIs

June 24th 2019

EP. 4: Importance of Compliance With TKIs in Treatment of CML

June 24th 2019

EP. 5: Resistance to Targeted-TKI Treatment in Patients With CML

June 24th 2019

EP. 6: Frontline Treatment for CML With BCR-ABL-Targeted TKIs

June 24th 2019

EP. 7: Role of Ponatinib in Treatment of R/R CML

June 24th 2019

EP. 8: Early Intervention With Ponatinib in Treatment of CML

June 24th 2019

EP. 9: Bosutinib Versus Ponatinib in R/R CML

June 24th 2019

EP. 10: Adverse Events of Second-Generation TKIs Used in Treating CML

June 24th 2019

EP. 11: Dose-Related Adverse Events With Ponatinib When Treating CML

June 24th 2019

EP. 12: Treatment-Free Remission & Toxicities of Discontinuing CML Therapy

June 24th 2019

EP. 13: Challenges in Management of Chronic Phase CML

June 24th 2019

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer

Are the RASolute 302 Results Overstated for Daraxonrasib in PDAC?

FDA Approves Zanidatamab Combinations for First-Line HER2+ Advanced GEA

First Patient Dosed in Molecular Glue Degrader Trial for mCRPC

Behind the FDA Approval: “Historic” Iberdomide Trial Spotlights MRD End Point and Potential of CELMoDs Across Myeloma